The State Of The Off-Patent Union: AAM’s Murphy Sets Out US Achievements And Obstacles

Tariffs, PBMs, Biosimilar Streamlining And Supply Among Priorities

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".